Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 16/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | PDE2A | O00408 | 1/20 | 0.61 |
| ▸ | RGS12 | O14924 | 1/20 | 0.61 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.61 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.61 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.61 |
| ▸ | PDE6D | O43924 | 1/20 | 0.61 |
| ▸ | PDE8A | O60658 | 1/20 | 0.61 |
| ▸ | GMNN | O75496 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15065644 | 0.93 | SLC29A1 (0.55) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9565600 | 0.92 | SLC29A1 (0.53) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7446848 | 0.92 | SLC29A1 (0.53) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4417277 | 0.86 | SLC29A1 (0.47) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4077877 | 0.86 | SLC29A1 (0.47) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2458642 | 0.85 | SLC29A1 (0.46) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10038311 | 0.80 | SLC29A1 (0.75) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| Dipyridamole SCHEMBL29381078 | 0.76 | SLC29A1 (1.00) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30416820 | 0.76 | SLC29A1 (1.00) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| Dipyridamole SCHEMBL16119 | 0.76 | SLC29A1 (1.00) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSTY | 2022-03-24 | — | — | US | claimed |
| WO-2020150698-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-07-23 | — | — | WO | claimed |
| US-5346772-A | HAVING A HIGH LUMINANCE AND HIGH EMISSION EFFICIENCY | PIONEER ELECTRONIC CORPORATION (JP) | 1994-09-13 | — | — | US | claimed |
| JP-57209291-A | — | — | None | — | — | JP | disclosed |
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSTY | 2022-03-24 | — | — | US | disclosed |
| WO-2020150698-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-07-23 | — | — | WO | disclosed |
| US-9254289-B2 | Methods for treating eye disorders using dipyridamole | REMEDEYE INC. (US) | 2016-02-09 | — | — | US | disclosed |
| EP-2968328-A1 | COMPOSITIONS FOR USE IN TREATING EYE DISORDERS USING DIPYRIDAMOLE | Remedeye Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014141079-A1 | COMPOSITIONS FOR USE IN TREATING EYE DISORDERS USING DIPYRIDAMOLE | REMEDEYE INC (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275124-A1 | METHODS FOR TREATING EYE DISORDERS USING DIPYRIDAMOLE | REMEDEYE INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| EP-0523555-A1 | Pharmaceutical composition useful in inhibiting biological degradation of polymeric implantation material | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1993-01-20 | — | — | EP | disclosed |
| EP-0230234-B1 | USE OF IMIDAZOQUINAZOLINES FOR THE TREATMENT AND PREVENTION OF NEPHRITIS | DAIICHI SEIYAKU CO., LTD. (JP) | 1991-06-05 | — | — | EP | disclosed |
| US-4963541-A | INHIBIT BIOSYNTHESIS OF LEUKOTRIENES | ABBOTT LABORATORIES (US) | 1990-10-16 | — | — | US | disclosed |
| EP-0230234-A1 | Use of imidazoquinazolines for the treatment and prevention of nephritis | DAIICHI SEIYAKU CO., LTD. (JP) | 1987-07-29 | — | — | EP | disclosed |
| US-4427648-A | INTIMATE MIXTURE WITH ACID OR ACID SALT FOR INCREASED BIOAVAILABILITY, CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1984-01-24 | — | — | US | disclosed |
| JP-S57209291-A | PURIFICATION OF DIPYRIDAMOLE | KYOWA HAKKO KOGYO CO LTD | 1982-12-22 | — | — | JP | disclosed |
| US-4256747-A | ANTIINFLAMMATORY AGENTS, PYRIDO/2,3B//1,4/BENZODIAZEPIN-6-ONES | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-17 | — | — | US | disclosed |
| US-4249014-A | ANALGESICS, ANTISPASMODICS, ANTIINFLAMMATORY VASODILATORS | INNOTHERA (FR) | 1981-02-03 | — | — | US | disclosed |
| EP-0019586-A1 | Antithrombotic combination formulas | CIBA-GEIGY AG (CH) | 1980-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | PYGB, PRKG1, ACHE | SLC29A1 2272/4885MEN1 4688/4885CYP3A4 2031/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | SLC29A1 1552/4885MEN1 4127/4885CYP3A4 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.